Retatrutide Canada: Triple-Agonist Research Peptide Guide (2026)

By the ThePeptide Research Team  ·  Verified against third-party COA lot RETA-0626-01 (Testides)  ·  Last updated July 2026

Retatrutide (development code LY-3437943) is an investigational triple-hormone-receptor agonist that activates the GIP, GLP-1, and glucagon receptors from a single lipidated peptide. Developed by Eli Lilly, it is the first triple agonist to reach Phase 3 and the current frontier of incretin-based metabolic research. This guide is a complete reference for Canadian laboratory researchers: molecular profile, mechanism, pharmacokinetics, the Phase 2 and Phase 3 TRIUMPH data, safety findings, third-party purity, reconstitution, and domestic sourcing of Retatrutide 10mg.

What Is Retatrutide?

Retatrutide is a synthetic peptide engineered to act on three metabolic hormone receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCGR) receptor. This "triple agonist" design distinguishes it from earlier incretin compounds that engage only one or two of those pathways — the single-target GLP-1 agonist semaglutide and the dual GIP/GLP-1 agonist tirzepatide.

In the research literature, retatrutide has been studied primarily as a candidate for obesity and related metabolic conditions. It is supplied for laboratory work as a lyophilized (freeze-dried) powder that is reconstituted with a suitable solvent before in-vitro or preclinical experimentation. Because it remains investigational and has no marketing approval from any regulator, all handling occurs within a research-use-only framework.

Molecular Profile

Retatrutide is a large, lipidated peptide of 34 amino acids, produced by solid-phase peptide synthesis and carrying a fatty-acid modification. That lipidation is functionally important: it promotes reversible binding to serum albumin, which is the structural basis for the extended circulation time discussed in the pharmacokinetics section below.

Verifying identity and purity against a Certificate of Analysis is standard practice before a lot enters any protocol. ↑ Back to top

The Triple-Agonist Mechanism: Why It's Different

The defining feature of retatrutide is that it combines three complementary signaling pathways in one molecule. Each receptor contributes a different physiological effect observed in the published research:

• GLP-1 receptor — associated with enhanced glucose-dependent insulin secretion and appetite modulation.
• GIP receptor — a second incretin pathway that acts alongside GLP-1 signaling.
• Glucagon (GCGR) receptor — the added third arm, associated with increased energy expenditure and hepatic lipid metabolism.

This is precisely where retatrutide diverges from its comparators. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a single GLP-1 agonist. Retatrutide layers glucagon-receptor agonism on top of the GIP + GLP-1 activity, making it the first triple agonist to advance to Phase 3. Researchers hypothesize that pairing appetite-related incretin signaling with a metabolic-rate pathway is what drives the larger weight reductions reported in its trials — the mechanism explored in depth in our three-way comparison guide. ↑ Back to top

Pharmacokinetics & Half-Life

Retatrutide's fatty-acid lipidation gives it an extended elimination half-life that supports the once-weekly dosing schedule used throughout its clinical program. In the published trials the compound was administered once weekly and titrated stepwise, reflecting a molecule that reaches steady state slowly — the same pharmacokinetic property behind the four-week dose-escalation intervals detailed in our research dosing reference.

For laboratory work, the practical consequences are that the reconstituted peptide is handled as a stable weekly-cadence research material and that concentration accuracy matters when preparing working solutions — use the reconstitution calculator to convert vial mass and solvent volume into a precise mg/mL concentration. ↑ Back to top

Clinical Research: Phase 2 and TRIUMPH Phase 3 Data

Two bodies of published data anchor retatrutide's scientific profile. The figures below are reported outcomes from the trials themselves — they describe the doses administered to trial participants under clinical supervision and are not guidance for any reader.

In the Phase 2 obesity trial in the New England Journal of Medicine (Jastreboff et al., 2023), the 12 mg once-weekly dose achieved approximately 24.2% mean body-weight reduction at 48 weeks. Eli Lilly then announced topline results from Phase 3 TRIUMPH-1 in May 2026: the 12 mg once-weekly dose produced 30.3% average weight loss at 104 weeks (28.3% at 80 weeks) in a main population of n=2,339.

Primary documentation: the NEJM Phase 2 paper and the ClinicalTrials.gov TRIUMPH listings. ↑ Back to top

Safety & Adverse Events in Trials

As with other incretin agonists, the adverse events reported in the retatrutide trials were predominantly gastrointestinal and dose-dependent. In the TRIUMPH-1 Phase 3 topline results, the most common adverse events at the 12 mg dose were:

These figures are why the trials used gradual dose escalation rather than starting at the maintenance dose. For a fuller treatment of the reported tolerability profile, see our companion article on retatrutide side effects and what the clinical research shows. All figures describe outcomes in the supervised clinical trial population and are reported here for scientific reference only. ↑ Back to top

Retatrutide vs Tirzepatide vs Semaglutide

The three compounds represent successive generations of incretin-based research. The table lists receptor targets and the peak weight reduction reported in each compound's pivotal trial. Each figure comes from a different trial and should be read in that context, not as a head-to-head comparison.

The consistent pattern — single → dual → triple receptor engagement tracking with larger reported reductions — is examined in full in our Semaglutide vs Tirzepatide vs Retatrutide comparison. ↑ Back to top

Research Applications

In a laboratory setting retatrutide is used as a reference compound for investigating triple-receptor incretin pharmacology: comparative agonist potency across GIP, GLP-1, and glucagon receptors; receptor-signaling and downstream metabolic-pathway studies; and structure–activity work on lipidated long-acting peptides. Its position as the first triple agonist in Phase 3 makes it a frequent comparator in metabolic and energy-expenditure research alongside tirzepatide and semaglutide. These are research contexts only and do not describe any use in humans or animals. ↑ Back to top

Purity, COA & Third-Party Testing

For research integrity, compound purity is critical: impurities can confound assay results, introduce off-target activity, and undermine reproducibility. This retatrutide has been independently verified at 99.68% purity by HPLC-UV (214 nm), lot RETA-0626-01, tested by Testides, a third-party laboratory. Independent verification means the figure is not self-reported by the vendor.

A Certificate of Analysis documenting this result is available on the Retatrutide product page. If you want to validate a lot yourself, our guide on where to get research peptides tested in Canada walks through independent verification. ↑ Back to top

Reconstitution & Handling (Research Context)

Retatrutide ships as a lyophilized powder that must be reconstituted before laboratory use. In a general research context, lyophilized peptides are reconstituted with a suitable sterile solvent — commonly bacteriostatic water — added slowly down the vial wall rather than directly onto the powder, then gently swirled (not shaken) until fully dissolved.

Two resources make this precise: our reconstitution calculator converts vial mass and solvent volume into concentration and insulin-syringe units, and our guide to how much bacteriostatic water to add gives a vial-by-vial chart. Fine measurement is done with U-100 insulin syringes. These notes describe laboratory technique only and are not instructions for administration to any organism. ↑ Back to top

Storage & Stability

Lyophilized retatrutide is the most stable form: kept sealed, cool, and away from light, freeze-dried peptide powder is stable long-term, and many labs store powder frozen. Once reconstituted, the solution is less stable — store refrigerated at 2–8 °C, protect from light, avoid repeated warming, and do not freeze-thaw cycle the reconstituted material. Inspect for cloudiness or particulates before use in any assay. ↑ Back to top

Why Canadian Researchers Source Domestically

• No customs seizures — domestic shipments avoid border inspection delays and the confiscation risk that affects international peptide orders.
• Faster shipping — in-country logistics mean material arrives in days, not weeks, protecting cold-chain integrity and research timelines.
• CAD pricing — transparent Canadian-dollar pricing with no surprise currency conversion, duties, or brokerage fees.

For the full picture, see our guide to buying research peptides in Canada. ↑ Back to top

Shop Retatrutide 10mg — from $49.50 CAD →

Frequently Asked Questions

Related Research Resources

• Retatrutide 10mg (product page & COA)
• Semaglutide vs Tirzepatide vs Retatrutide comparison
• Tirzepatide Canada research guide · Semaglutide Canada research guide
• Retatrutide side effects: what the research shows
• Peptide reconstitution calculator · How much bacteriostatic water to add
• Research dosing & reconstitution reference
• Where to get research peptides tested in Canada
• How to buy research peptides in Canada

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972. Read the paper.
2. Eli Lilly and Company. "TRIUMPH-1 Phase 3 topline results." May 2026. investor.lilly.com.
3. The American Journal of Managed Care (AJMC). "Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial." ajmc.com.
4. Retatrutide (LY-3437943), CAS 2381089-83-2 — compound record. Reference entry.
5. ClinicalTrials.gov. TRIUMPH program listings. clinicaltrials.gov.